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The International Pre IID 2013 Satellite
Meeting on Autoimmune Bullous
Diseases (AIBDs) was held in Lu¨beck,
Germany, from 6th to 7th May 2013,
preceding the International Investigative
Dermatology (IID) meeting in Edinburgh,
UK. This Satellite Meeting followed the
tradition of the IID-associated symposia
on AIBDs in Kyoto (1993), Salzburg
(1998), and Otsu (2008). In total, 180
international researchers and clinicians
attended the meeting.
Plenary lectures covered the following
topics: (i) epidemiology and genetics of
AIBDs; (ii) diagnosis and novel disease
entities; (iii) cell biology of desmosomes
and disease pathways; (iv) cell biology
of hemidesmosomes and disease path-
ways; and (v) outcome measures and
novel treatments. In the exhibit of pos-
ters, approximately 60 abstracts were
presented. The meeting was flanked by
two satellite symposia. Importantly, the
meeting provided ample time for inter-
active discussions, critical analyses of
the progress achieved to date, and the
identification of questions that still
needed to be resolved.
PLENARY PRESENTATIONS
Epidemiology and genetics of AIBDs
Here, two speakers independently indi-
cated a sharp increase in bullous
pemphigoid (BP) incidence in various
European regions. Moreover, increased
mortality rates as well as an association
with neurological diseases were noted
(Langan et al., 2008). In addition to this
epidemiological research, unraveling
the genetic predisposition of AIBDs will
aid in future clinical decision making
and facilitate personalized medical care.
The results of the first genome-wide
association study (GWAS) in pemphigus
vulgaris patients were presented. The
study, which was recently published
in this journal, led to the identification
of ST-18 as a susceptibility gene in
pemphigus vulgaris (Sarig et al., 2012).
In addition to GWAS, functional and
metagenomic genetic studies are expected
to provide further insights into AIBD
pathogenesis. As an example of a func-
tional study, a strong association was
reported between allelic and copy number
variations in human Fc gamma receptor
genes and an increased susceptibility to
AIBD. This study was paralleled by
investigations on the impact of these
variations on neutrophil function in vitro.
As an example of a metagenomic study,
data on gene interactions, microbiota,
and autoimmune disease susceptibility
were presented, which subsequently
have also been published (Srinivas
et al., 2013).
Diagnosis and novel disease entities
A new terminology for AIBD was dis-
cussed focusing on both the target anti-
gen and autoantibody isotype. This
classification is based on our growing
understanding of the molecular biology
of AIBD, including the identification
of novel autoantigens (Dainichi et al.,
2009). In addition, novel methods for
serological AIBD diagnosis, such as
biochip mosaic-based and bioplex-
based techniques, were discussed.
Furthermore, the practical importance
of differentiating epidermolysis bullosa
acquisita (EBA) from other sub-epidermal
AIBDs, such as BP, using direct immuno-
fluorescence microscopy of the patient’s
skin and determining the fluorescence
pattern (e.g., either ‘‘n-serrated’’ or
‘‘u-serrated) was demonstrated with
audience participation (Terra et al.,
2013).
Cell biology of desmosomes and disease
pathways
Regarding pemphigus, the characteriza-
tion of anti-desmoglein antibodies
generated by phage display from pem-
phigus patients was presented. This
powerful technique facilitates a detailed
analysis of the B-cell immune response,
exemplified by following the B-cell
response in pemphigus patients over
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several years. Using this technique, it
was demonstrated that autoreactive
B-cell clones persist over a long period
of time. Furthermore, generation of an
autoimmune B-cell response to Dsg 3
relies on somatic mutations in response
to an unrelated antigen (Di Zenzo et al.,
2012). Interestingly, various Dsg
3-specific T cells not only contribute
to the generation of an anti-Dsg 3 IgG
response but also directly cause inter-
face dermatitis in vivo (Takahashi et al.,
2011). In addition, an environmental,
non-infectious agent (sand fly salivary
antigen) may drive the generation of
autoimmunity in pemphigus in ende-
mic pemphigus foliaceus (Qian et al.,
2012). Evidence for the pathogenicity of
non-desmoglein-specific autoantibodies
(e.g., autoantibodies directed against
desmocollin 3) in pemphigus was sum-
marized and discussed in detail (Rafei
et al., 2011; Kalantari-Dehaghi et al.,
2013).
This session also focused on the
involvement of signaling molecules in
the pathogenesis of pemphigus vulgaris
(e.g., the Dsg3-p38MAPK adhesion
receptor complex, which has been iden-
tified as a potential drug target in the
treatment of pemphigus; Spindler et al.,
2013). In addition, the role of apoptosis
in pemphigus was widely discussed: on
one hand, the evidence for Fas ligand
involvement in the pathogenesis of
blister formation in pemphigus was pro-
vided. On the other hand, data from skin
biopsies from pemphigus patients do not
support apoptotic involvement. Further-
more, in contrast with Dsg 3 antibodies,
Dsg 1 antibodies were shown to induce
widening between keratinocytes by
diminishing desmosome size and
number and altering plakoglobin distri-
bution. These observations support the
desmoglein non-assembly depletion
hypothesis as a dominant mechanism
for acantholysis in pemphigus foliaceus
(Oktarina et al., 2011). The actin-binding
protein adducin may also control blister-
ing in pemphigus as it was reported to
regulate Dsg 3 protein expression.
Cell biology of hemidesmosomes and
disease pathways in pemphigoid
The mechanisms involved in blister for-
mation in pemphigoid disease were a
focus of this session. Novel data from
the BP neonatal mouse model (Liu et al.,
1993) indicate that blister induction
completely depends on IL-1 signaling,
particularly IL-1b and inflammasome
activation. In dermatitis herpetiformis,
epidermal transglutaminase (TG3) dif-
fuses from human epidermis into the
upper dermis. The subsequent binding
of anti-TG3 IgA initiates the blistering
cascade in dermatitis herpetiformis.
Furthermore, the pathogenic relevance
of anti-IgE antibodies and cleavage
site–specific antibodies in BP were
discussed. Convincing evidence was
presented for the contribution of anti-
BP180 IgE in the pathogenesis of BP,
which is mediated by Fc-receptor-
independent effects (Messingham et al.,
2011) and the regulation of eosinophil
functions. In contrast, the pathogenic
relevance of cleavage site–specific
autoantibodies, as studied in the
COL17-humanized mouse model of BP
(Nishie et al., 2007), needs to be further
evaluated. In addition to targeting
blister-inducing mechanisms in pemphi-
goid, the pathways involved in blister
resolution, such as Flightless I, may also
be used as novel treatments (Kopecki
et al., 2013). After a review of the
molecular organization within hemides-
mosomes, the biology of type VII
collagen (COL7) and its potential use
as protein-based treatment in recessive
dystrophic epidermolysis bullosa (RDEB)
was discussed given that recombinant
COL7 forms new anchoring fibrils in
RDEB patients after intravenous injec-
tion (Wang et al., 2013). Novel insights
into the mechanisms leading to loss of
tolerance in EBA were also presented:
epidemiologic observations, HLA geno-
typing of EBA patients, and data from
mouse models of this disease provide
strong evidence for a genetic contri-
bution. In addition, experimental data
indicate that specific T-cell subsets and
cytokines are involved in the initiation
of the autoimmune response (Ludwig
et al., 2013).
Outcome measures and novel treatments
In this final session, the attendees dis-
cussed the importance of outcome mea-
sures for AIBDs (Daniel et al., 2012) to
determine disease activity, thereby
offering the possibility of comparing
therapeutic outcomes among AIBD
studies. In an extension of a previous
study on the clinical and molecular
effects of rituximab treatment in
pemphigus vulgaris (Colliou et al.,
2013), initial data were presented from
a randomized controlled study com-
paring rituximab and corticosteroids to
corticosteroids alone in pemphigus
vulgaris patients. Use of veltuzumab, a
humanized anti-CD20 mAb, was dis-
cussed as an alternative treatment option
in rituximab-refractory pemphigus. The
evidence of immunoapheresis in bullous
diseases was summarized (Schmidt and
Zillikens, 2013), and the outline of an
ongoing prospective controlled multi-
center trial of immunoapheresis in
pemphigus patients was discussed. The
final results from this study are expected
by the end of 2015.
POSTER SESSIONS
Several hours were exclusively reserved
for discussions of the posters (n¼58).
Poster prizes were awarded to Volker
Spindler (Munich) for the work entitled
‘‘Peptide-mediated prevention of pem-
phigus skin blistering in mice’’ and to
Yvonne Exner (Marburg) for her work
entitled ‘‘IgG autoantibodies against car-
boxy-terminal epitopes of desmoglein 3
are pathogenic in vitro’’.
SATELLITE MEETINGS
Meeting of the International Autoimmune
Blistering Diseases Genetics Consortium
On 6th May, over 30 conference parti-
cipants met to discuss the future direc-
tion of AIBD genetic studies. The
participants agreed that relatively small
patient numbers and ethnic differences
are the major challenges for AIBD
genetic studies. To overcome these
challenges, joint efforts have been made
to bring together all existing and recruit-
ing cohorts. This effort can be achieved
within the framework of the Interna-
tional Autoimmune Blistering Diseases
Genetics Consortium. Following the first
GWAS in pemphigus vulgaris patients
(Sarig et al., 2012), the participants
expect results from additional GWAS
in BP, mucous membrane pemphigoid,
and pemphigus within the next 2–3
years. The participants also agreed that
novel technologies, such as next-gen-
eration sequencing, will be the driving
force behind the progress in this field in
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the next years. Collectively, the identifi-
cation of susceptibility genes will aid in
the development of novel compounds
targeting the respective pathways.
EBA Consensus Meeting
On 7th May, 35 registrants joined this
4th and final meeting in a series of
international EBA consensus meetings
cochaired by Dedee Murrell (Australia)
and Victoria Werth (USA). Previous
meetings were held at the AAD, SID,
and EADV over the preceding 2 years.
Definitions agreed upon at the pre-
vious meetings and the EBA disease area
index (EBADAI) were reviewed and dis-
cussed. One challenge in the develop-
ment of a disease extent tool for both
EBA and mucous membrane pemphi-
goid is scoring ocular involvement. For
practical reasons, it would be easier if
dermatologists could score ocular invol-
vement themselves. However, a simple
scoring sheet could ideally be used by
ophthalmologists to ensure accuracy.
Two scoring systems for ocular involve-
ment were presented and widely dis-
cussed (Munyangango et al., 2013).
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